SHIDA HOU^1,#, TIANJUN LAN^2,#, YAOCHENG YANG^3,#, PEISHENG LIANG¹, XIN LIU^4,5, JUNJIE WANG⁶, ZHIFENG CHEN⁷, RONGSHENG ZENG^1,*, ZIJING HUANG^8,*

BIOCELL, Vol.47, No.12, pp. 2641-2660, 2023, DOI:10.32604/biocell.2023.043291

Abstract Background: 5-Methylcytosine (m5C) methylation contributes to the development and progression of various malignant tumors. This study aimed to explore the potential role of m5C methylation regulators (m5CMRs) in head and neck squamous cell carcinoma (HNSCC). Methods: The transcription data of HNSCC samples were obtained from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases. Subsequently, the m5C patterns in HNSCC were evaluated based on 14 m5CMRs. Then, the m5Cscore was developed to quantify m5C patterns by using principal component analysis (PCA) algorithms. Two single-cell RNA sequencing datasets and various methods were employed to assess the prognostic value… More >

SUNG HEE LIM^1,#, HEE JIN CHO^1,2,3,#, KYOUNG-MEE KIM⁴, HO YEONG LIM¹, WON KI KANG¹, JEEYUN LEE¹, YOUNG SUK PARK¹, HEE CHEOL KIM^5,*, SEUNG TAE KIM^1,*

Oncology Research, Vol.31, No.6, pp. 855-866, 2023, DOI:10.32604/or.2023.030374

Abstract Background: Although bevacizumab is an important treatment for metastatic colorectal cancer (CRC), not all patients with CRC benefit from it; in unselected patient populations, only modest survival benefits have been reported. Methods: We evaluated clinical outcomes in 110 patients using comprehensive molecular characterization to identify biomarkers for a response to bevacizumab-containing treatment. The molecular analysis comprised whole-exome sequencing, ribonucleic acid sequencing, and a methylation array on patient tissues. Results: Genomic and molecular characterization was successfully conducted in 103 patients. Six of 103 CRC samples were hypermutated, and none of the non-hypermutant tumors were microsatellite unstable. Among those 103 patients, 89… More >

WENHAO XU^1,#, HAOMING LI^2,#, YASIR HAMEED³, MOSTAFA A. ABDEL-MAKSOUD⁴, SAEEDAH MUSAED ALMUTAIRI⁴, AYMAN MUBARAK⁴, MOHAMMED AUFY⁵, WAEL ALTURAIKI⁶, ABDULAZIZ J. ALSHALANI⁶, AYMAN M. MAHMOUD^7,*, CHEN LI^8,*

Oncology Research, Vol.31, No.5, pp. 819-831, 2023, DOI:10.32604/or.2023.029414

Abstract N6-methyladenosine methylation (m6A) is a common type of epigenetic alteration that prominently affects the prognosis of tumor patients. However, it is unknown how the m6A regulator affects the tumor microenvironment (TME) cell infiltration in adrenocortical carcinoma (ACC) and how it affects the prognosis of ACC patients yet. The m6A alteration patterns of 112 ACC patients were evaluated, furthermore, the association with immune infiltration cell features was investigated. The unsupervised clustering method was applied to typify the m6A alteration patterns of ACC patients. The principal component analysis (PCA) technique was taken to create the m6A score to assess the alteration pattern… More >

YANPING JIN¹, JIANPING QIU¹, XIUFANG LU¹, YAN MA¹, GUOWEI LI^2,*

Oncology Research, Vol.31, No.2, pp. 169-179, 2023, DOI:10.32604/or.2023.027815

Abstract Previous study revealed that ferritin heavy chain-1 (FTH1) could regulate ferritinophagy and affect intracellular Fe²⁺ content in various tumors, while its N6-methyladenosine (m6A) RNA methylation was closely related the prognosis of ovarian cancer patients. However, little is known about the role of FTH1 m6A methylation in ovarian cancer (OC) and its possible action mechanisms. In this study we constructed FTH1 m6A methylation regulatory pathway (LncRNA CACNA1G-AS1/IGF2BP1) according to related bioinformatics analysis and research, through clinical sample detections we found that these pathway regulatory factors were significantly up-regulated in ovarian cancer tissues, and their expression levels were closely related to the… More >

QIAO ZHOU^1,2,3, JIAN LIU^2,4, LING XIN⁴, YANYAN FANG^2,4, LEI WAN^2,4, DAN HUANG^2,4, JINCHEN GUO¹, JIANTING WEN^2,4

BIOCELL, Vol.47, No.4, pp. 761-772, 2023, DOI:10.32604/biocell.2023.026698

Abstract The pathophysiology of osteoarthritis (OA) is multifactorial, with the primary risk factors being obesity, age, environmental variables, and genetic predisposition. The available evidence suggests that genetic diversity does not adequately account for all clinical characteristics and heterogeneity of OA. Genetics has emerged as a nascent and crucial area of research in OA. The epigenetic module presents a potential link between genetic and environmental risk factors and the susceptibility and pathogenesis of OA. As a critical epigenetic alteration, DNA methylation has been shown to have an important role in the etiology of OA and is a viable biomarker for predicting disease… More >

YOULIN TUO, XUBAO LIU^*

BIOCELL, Vol.47, No.2, pp. 319-328, 2023, DOI:10.32604/biocell.2023.025250

Abstract Retinoic acid receptor responder 3 (RARRES3) has been characterized as a tumor suppressor in multiple types of cancer. This study aimed to examine the expression profile of RARRES3 across the PAM50 subtypes of breast cancer. The DNA methylation status of RARRES3 was checked in the basal-like subtype, and the underlying mechanisms of its dysregulation were explored. RNA-sequencing (seq) and methylation data from The Cancer Genome Atlas were used for in-silico analysis. Basal-like representative SUM149 and MDA-MB-468 cell lines were used for in vitro and in vivo studies. Compared to tumor-adjacent normal tissues, only the basal-like tumor tissues had significantly downregulated… More >

Noureldin Eissa^1,2,*, Uswah Khairuddin^1,3, Rubiyah Yusof¹, Ahmed Madani²

CMC-Computers, Materials & Continua, Vol.74, No.2, pp. 2817-2838, 2023, DOI:10.32604/cmc.2023.033632

Abstract Epigenetics is the study of phenotypic variations that do not alter DNA sequences. Cancer epigenetics has grown rapidly over the past few years as epigenetic alterations exist in all human cancers. One of these alterations is DNA methylation; an epigenetic process that regulates gene expression and often occurs at tumor suppressor gene loci in cancer. Therefore, studying this methylation process may shed light on different gene functions that cannot otherwise be interpreted using the changes that occur in DNA sequences. Currently, microarray technologies; such as Illumina Infinium BeadChip assays; are used to study DNA methylation at an extremely large number… More >

Minghui Cui, Limei Lin, Jie Zhang, Xin Song, Shuo Wang, Jing Dong, Xuelei Zhao, Yuehong Long^*, Zhaobin Xing^*

Phyton-International Journal of Experimental Botany, Vol.91, No.12, pp. 2649-2668, 2022, DOI:10.32604/phyton.2022.021631

Abstract Mevalonate pyrophosphate decarboxylase is a kind of key enzyme in the terpenoid synthesis pathway in Eleutherococcus senticosus. The results of bisulfite sequencing showed that there were three kinds of samples with a low (0.68%), medium (0.72%) and high (0.79%) DNA methylation ratio in the promoter of MDD in E. senticosus, respectively. The transcriptome sequencing results showed that the expression of MDD in E. senticosus was significantly up-regulated in the types with low DNA methylation ratios of MDD (P < 0.05). There was a significant negative correlation between the saponin content in E. senticosus and the DNA methylation ratio of MDD… More >

Yulong Jin^*, Li Xu^*, Xiaodong Wu^†, Juan Feng^*, Mimi Shu^*, Hongtao Gu^*, Guangxun Gao^*, Jinyi Zhang^‡, Baoxia Dong^*, Xiequn Chen^*

Oncology Research, Vol.27, No.6, pp. 729-737, 2019, DOI:10.3727/096504018X15443011011637

Abstract Multiple myeloma (MM) is a hematopoietic malignancy characterized by the clonal proliferation of antibodysecreting plasma cells. Bortezomib (BZM), the first FDA-approved proteasome inhibitor, has significant antimyeloma activity and prolongs the median survival of MM patients. However, MM remains incurable predominantly due to acquired drug resistance and disease relapse. -Catenin, a key effector protein in the canonical Wnt signaling pathway, has been implicated in regulating myeloma cell sensitivity to BZM. Decitabine (DAC) is an epigenetic modulating agent that induces tumor suppressor gene reexpression based on its gene-specific DNA hypomethylation. DAC has been implicated in modulating Wnt/ -catenin signaling by promoting the… More >

Rosa Della Monica^*1, Mariella Cuomo^*†1, Roberta Visconti^‡, Annabella di Mauro^§, Michela Buonaiuto^*, Davide Costabile^*†, Giulia De Riso^†, Teodolinda Di Risi^*, Elia Guadagno^¶, Roberto Tafuto^#, Sabrina Lamia^**, Alessandro Ottaiano^††, Paolo Cappabianca^#, Maria Laura Del Basso de Caro^¶, Fabiana Tatangelo^§, Juergen Hench^‡‡, Stephan Frank^‡‡, Salvatore Tafuto^**, Lorenzo Chiariotti^*†

Oncology Research, Vol.28, No.9, pp. 837-845, 2020, DOI:10.3727/096504021X16214197880808

Abstract Unresectable neuroendocrine neoplasms (NENs) often poorly respond to standard therapeutic approaches. Alkylating agents, in particular temozolomide, commonly used to treat high-grade brain tumors including glioblastomas, have recently been tested in advanced or metastatic NENs, where they showed promising response rates. In glioblastomas, prediction of response to temozolomide is based on the assessment of the methylation status of the MGMT gene, as its product, O6 -methylguanine-DNA methyltransferase, may counteract the damaging effects of the alkylating agent. However, in NENs, such a biomarker has not been validated yet. Thus, we have investigated MGMT methylation in 42 NENs of different grades and from… More >